Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Metoclopramide Hydrochloride
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Metoclopramide Injection, USP in the U.S. Market
Details : Reglan-Generic (metoclopramide) is a 5-HT3a and D2 receptor inhibitor small molecule drug candidate indicated for the treatment of diabetic gastroparesis, & prevention of nausea and vomiting.
Brand Name : Reglan-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2024
Lead Product(s) : Metoclopramide Hydrochloride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Metoclopramide Hydrochloride
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Evoke Pharma Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List
Details : GIMOTI (metoclopramide) nasal spray, for relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults, has been added to Texas Medicaid PDL, supports reimbursement for GIMOTI on Texas Medicaid formulary and associated program.
Brand Name : Gimoti
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : Metoclopramide Hydrochloride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Metoclopramide Hydrochloride
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®
Details : Gimoti is Evoke’s nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis. The patent covers methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.
Brand Name : Gimoti
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 02, 2021
Lead Product(s) : Metoclopramide Hydrochloride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?